Objectives. Recently a EULAR-taskforce defined arthralgia suspicious for progression to RA, in order to allow inclusion of homogeneous sets of arthralgia patients in clinical studies. This longitudinal study aimed (i) to validate this definition in arthralgia patients in whom rheumatologists felt that imminent RA was more likely than other arthralgias [clinically suspect arthralgia (CSA)], that is, the target population fulfilling the entry criterion, and (ii) to explore the performance in arthralgia patients who were referred to secondary care prior to rheumatological evaluation, hence ignoring the entry criterion.
Introduction
Recently, a EULAR taskforce has defined arthralgia suspicious for progression to RA (supplementary Table S1 , available at Rheumatology Online) [1] . This was done as it is hypothesized that very early treatment initiation allows better disease modification and may even prevent RA development [2] . Therefore, the field of RA is currently shifting towards performing trials in very early disease phases [3, 4] . A challenging aspect is the accurate identification of patients with imminent RA. In order to allow the inclusion of homogeneous sets of patients in clinical studies, the EULAR taskforce arrived at a consensus on the definition of arthralgia suspicious for progression to RA [1] .
In daily practice, clinical expertise of the rheumatologist serves well to differentiate patients with arthralgia at risk for RA from patients with joint symptoms not at risk for RA [5] . A previous study revealed that the rheumatologists' suspicion on imminent RA was associated with an odds ratio (OR) of 55 to progress to RA. Also the sensitivity (80%) and specificity (93%) were high [5] . Despite the high discriminative accuracy of the rheumatologists' pattern recognition, an obvious drawback of using clinical expertise as an inclusion criterion for scientific studies is its subjectivity. To reduce this subjectivity, the EULAR taskforce sought to express clinical expertise in measurable clinical parameters [1] . It was demonstrated that these parameters were accurate in translating clinical expertise in clinical parameters (area under the receiver operating characteristic curve 0.92) [1] , but the performance of this definition with arthritis development as long-term outcome has not yet been determined.
The definition was intended for use in patients with arthralgia, without clinical arthritis, in whom imminent RA was considered more likely than other diagnoses. Hence, this entry criterion implies that the definition is used on top of the rheumatologist's evaluation. The main aim of this study was to validate the definition in patients that rheumatologists (based on their clinical expertise) identified with clinically suspect arthralgia (CSA) [6] . Importantly, these patients were identified as having CSA by rheumatologists without knowledge of the current definition. In addition, as it has been questioned if the entry criterion of clinical expertise can be omitted [7] , the definition was also explored in arthralgia patients referred by general practitioners (GPs) who were not yet evaluated by rheumatologists.
Methods

Patients
Two sets of patients with recent-onset arthralgia of the small joints were studied. Both study protocols were approved by the local medical ethical committees and patient consent was obtained when required by the local medical ethical committee. For the patients from the Leiden CSA-cohort this was the local medical ethical committee of the Leiden University Medical Center. The whole study (for the Swedish part) was approved by the Regional Ethical review board in Umeå , Sweden. No additional ethical approval was required for this study.
The Leiden CSA cohort Two hundred and forty-one patients consecutively included in the CSA cohort between April 2012 and March 2015 were studied (supplementary Fig. S1 , available at Rheumatology Online). The inclusion criterion was recent-onset (<1 year) arthralgia in small joints, that was considered to be at risk for progression to RA based on the clinical expertise of the rheumatologist [6] . Inclusion was based on clinical presentation as auto-antibody status was generally unknown at the time of inclusion. In our region auto-antibodies were generally not tested by GPs [8] , which is in accordance with national guidelines that promote quick referral rather than ordering tests [9] . Thus, additional tests were done after inclusion, which usually took place at first presentation. Patients in whom explanations/diagnoses other than imminent RA were considered more likely were not included in the CSA cohort. All studied patients were included before the EULAR definition was developed, so that rheumatologists were not aware of its content. Information on five of the seven clinical parameters defining arthralgia suspicious for progression to RA was collected in case report forms. Data on two parameters (most severe symptoms in early morning and presence of a first degree relative with RA) was collected in retrospect by going through the medical records. Patients were followed prospectively over a period of 2 years; none of the patients were treated with DMARDs in the phase of arthralgia. Detailed information about the CSA cohort is provided in the supplementary methods, available at Rheumatology Online, and has been described elsewhere [6] .
Patients referred to secondary care (before rheumatological evaluation)
Patients who were referred in 2010 and 2011 by GPs to the university hospital in Umeå in Sweden (the only referral centre in the county) with arthralgia of the small joints of the hands and/or feet for <2 years were selected in retrospect by going through all the referral letters (n = 113, supplementary Fig. S1 , available at Rheumatology Online). Patients referred with arthritis (based on the referral letter) were excluded. In the Umeå data, information on all parameters at first presentation and on the outcome during at least 2 years' follow-up were collected in retrospect by going through all the patients' records both from the rheumatologist and the GP.
External standard
Development of arthritis confirmed at physical examination by a rheumatologist (by joint palpation and observing the presence of synovial swelling) was the primary outcome. Fulfilment of the 2010 criteria for RA [10] and DMARD initiation at the time of arthritis development were used as secondary outcomes.
Cut-off for a positive definition
The EULAR taskforce concluded that presence of 53/7 parameters provided a sensitive definition when clinical expertise was used as the reference [1] . Assuming that a high specificity can be obtained by adding laboratory or imaging tests to the clinical definition, it was anticipated that the clinical definition should rather be sensitive than specific. Therefore, in this study a positive definition was defined as 53/7 parameters present. Sub-analyses were performed with 52/7 or 54/7 parameters as cut-off.
Statistical analyses
A Cox-proportional hazard regression analysis was used to compare the hazard on arthritis development in patients who fulfilled the definition compared with those who did not. Missing values were imputed using chained equations [11] . Test characteristics were determined with arthritis development <2 years' follow-up as reference.
Results
Validation of the EULAR definition in CSA Table 1 depicts the baseline characteristics of the patients identified with CSA by rheumatologists. The location of symptoms of both groups of patients is presented in supplementary Table S2 , available at Rheumatology Online. One hundred and seventy-eight of the 241 patients (74%) fulfilled the definition. Forty-four CSA patients (18%) developed arthritis after a median duration of 16 weeks (interquartile range (IQR): 622 weeks). Definition-positive CSA patients had an increased hazard on arthritis development. The hazard ratio was 2.1 (95% CI: 0.9, 4.7), indicating that fulfilment of the EULAR definition resulted in a two-fold increased hazard on progression to arthritis, compared with arthralgia patients who were considered as having CSA by their rheumatologist but who did not fulfil the definition. Subsequently the test characteristics of the definition were evaluated in CSA patients who completed 2 years' follow-up (n = 133), yielding a sensitivity of 84% and a positive predictive value (PPV) of 30% (Dutch patients identified as CSA by rheumatologists are shownin Table 2 ).
Sensitivity analyses
Similar results were obtained for 2010-RA or DMARD initiation at the time of arthritis development as outcome. A cut-off of 52/7 parameters to define a positive test resulted in a slightly higher sensitivity (91%), a cut-off of 54/7 parameters in a lower sensitivity (38%) (supplementary Table S3 , available at Rheumatology Online).
Exploration of the EULAR definition in patients referred to secondary care but before rheumatological evaluation Baseline characteristics of the patients referred to the Umeå university hospital are depicted in Table 1 
Discussion
This is the first study that validated the recently developed EULAR definition for arthralgia suspicious for progression to RA in a longitudinal study [1] . It was observed that a positive definition is sensitive and valuable when used to support the expert's opinion on imminent RA. The definition was not intended as a diagnostic tool, but to induce homogeneity in patients who are considered to be at risk for RA in order to promote the inclusion of homogeneous groups of arthralgia patients in studies. The taskforce that developed the definition stated that it should only be applied in secondary care in patients in whom, according to the rheumatologist, imminent RA is the most likely diagnosis [1] . The current data demonstrate that patients who were considered to have CSA but were definition-negative indeed had a relatively low risk for RA development. Hence the definition served well to fine-tune the patient selection and resulted in a more homogeneous patient group.
Although the EULAR definition is not a set of classification criteria, the statement that the definition should be applied in arthralgia patients in whom imminent RA is considered more likely than other explanations resembles the entry criteria of the 2010 criteria for RA [10] . It is also in line with recommendations on how classification criteria should be used in general; namely in patients in whom a clinical diagnosis (or in this case a suspicion of imminent RA) has been made [12, 13] .
In addition to its original designation, the question has been raised as to whether the definition may also be used without considering the entry statement, in which case it could for instance also be used as a triage system for patients referred to secondary care or as a referral guideline in primary care [7] . Our present data on a (rather small) population of referred patients in which the entry criterion was ignored suggest that a positive definition was not discriminative in such a setting. Yet these data underline the necessity of maintaining the entry statement in the definition.
A recent study from our group (partly evaluating patients that were also studied here) demonstrated that the rheumatologists' expertise served well to differentiate arthralgia at risk for RA from other arthralgias [5] . In this study 1936 newly presenting arthralgia patients were evaluated, of whom 1791 were considered as arthralgia without clear explanation at the first presentation and 145 were identified as CSA, showing that CSA make up a small proportion of arthralgia patients. The identification of CSA by rheumatologists associated with an OR of 55 for RA development [5] . When the EULAR definition was applied on top of the pattern recognition of rheumatologists in the 145 CSA patients, those with a positive definition (100 of the 145) had an OR of 2.1 for RA development compared with CSA patients with a negative definition. Hence, used in this order, clinical expertise not only had the highest OR for RA development but also the largest contribution in the funnel of patient selection. Based on these data, 100 out of 1936 arthralgia patients were suspicious for progression to RA based on the clinical presentation. Subsequently, information on biomarkers is required for further risk stratification. This re-analysis of previously published data also suggests that the EULAR definition serves to further refine patient identification and supports the finding on the relevance of the rheumatologists' suspicion on imminent RA. Table 1 revealed an evident difference in the prevalence of MCP symptoms and a positive MCP-squeeze test between the two groups of arthralgia patients. This is the result of the difference in patient selection. Patients Only patients who completed 2 years of follow-up were included (n = 133). Of these patients, 32 developed arthritis within 2 years of follow-up, 24 fulfilled the 2010 criteria for RA at the time of arthritis development and 28 were started on DMARDtherapy.
b
One hundred and thirteen patients of whom 10 developed arthritis within 2 years of follow-up. At the time of arthritis development, three fulfilled the 2010 criteria for RA at the time of arthritis development and nine were started on DMARD therapy. CSA: clinically suspect arthralgia; NPV: negative predictive value; PPV: positive predictive value.
identified as CSA by their rheumatologists more often had MCP involvement, as demonstrated by supplementary Table S2 , available at Rheumatology Online, in contrast to symptoms located in other hand or foot joints. Apparently MCP involvement was considered important in this respect. Importantly, these patients were included in the CSA cohort before the EULAR definition was developed, and hence there was no circularity. Nonetheless the experts in the taskforce also weighted MCP involvement heavily and included two items on MCPs in the definition. Thus both the rheumatologists involved in collecting the present data and those that participated in the EULAR taskforce agreed on the relevance of MCP symptoms.
Our results show that the PPV for arthritis development of the EULAR definition alone was not high. This was expected already at the time of derivation, as the EULAR taskforce considered it unlikely that clinical factors alone would be sufficient to identify imminent RA [1] . Future criteria for imminent RA will most likely consist of both clinical findings and results from additional investigations. This is in line with other criteria, such as the 2010 criteria for RA [10] This study has limitations. Access to rheumatology outpatient clinics was less easy for GPs in the Umeå region than in Leiden. In addition, patients referred with arthritis to Umeå were not studied, even if arthritis was not confirmed by a rheumatologist. Hence, some patients at risk for RA may have been excluded. Another limitation is that some data were collected from medical records. Although no standardized definitions were used (e.g. for difficulty making a fist), data were used as recorded by rheumatologists. Finally, both data-sets were relatively small. Evaluation in larger cohorts is needed.
In summary, this first longitudinal validation study evaluating the EULAR definition for arthralgia suspicious for progression to RA demonstrated that a positive definition supports the expert's opinion on imminent RA, and thereby helps to increase homogeneity in patients considered to be at risk for RA. Galaxy sign in alveolar sarcoidosis: An unusual radiological presentation of Lofgren's syndrome A 27-year-old Caucasian woman presented in February 2017 with a 4-week history of symmetrical joint pain and swelling involving the ankles and knees, rash on lower limbs consistent with erythema nodosum and intermittent chest pain. No environmental triggers were identified. A chest radiograph revealed bilateral symmetrical hilar lymphadenopathy, and some atypical ill-defined air space opacities were seen in the right upper lobe (Fig. 1A) . Blood tests demonstrated CRP of 199.5 mg/l (normal <5 mg/l) and serum angiotensin converting enzyme levels were 76 IU/l (normal 2070 IU/l). A diagnosis of Lofgren's syndrome was made. Subsequent high-resolution CT confirmed bilateral hilar lymphadenopathy and also demonstrated the galaxy sign typical of alveolar sarcoidosis (Fig. 1B) . The patient made a good clinical and radiological recovery with low dose oral prednisolone, and a follow-up chest X-ray 5 months after the initial presentation showed an almost complete resolution of the atypical pulmonary opacities and improvement of the hilar lymphadenopathy Alveolar sarcoidosis is an uncommon radiological presentation of acute pulmonary sarcoidosis (reported in 411% of patients) [1, 2] . Affecting mostly the younger age group, it is often accompanied by mediastinal lymphadenopathy [1] . The galaxy sign on high-resolution CT describes the ill-defined opacities resulting from confluence of interstitial granulomas [2] . Spontaneous radiographic resolution is usually observed.
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